Anti-Human CX3CL1 (Clone CPTC-CX3CL1-1) – Purified No Carrier Protein

Human CX3CL1 peptide sequence ALGTSPELPTGVTGSSGTR

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FSAI158R-4H6 activity is directed against human CX3CL1 peptide sequence ALGTSPELPTGVTGSSGTR.

CPTC-CX3CL1-1

CX3CL1 is a transmembrane chemokine that exists as two isoforms: a static membrane-bound glycoprotein that mediates cell adhesion or a cleaved soluble isoform that is chemotactic¹. Both isoforms mediate signaling via the CX3CR1 receptor, which is exclusively expressed on microglial cells, but exhibit different affinities and biological activities depending on the specific mediators involved. Functions in normal biology include roles in the construction of the neural network, synapse maturation, plasticity, cognitive function, immune processes, and as a regulator of microglia activation in response to brain injury or inflammation. CX3CL1 is also involved in anti-viral and anti-tumor immunity via roles in the maintenance of effector memory cytotoxic T cell populations² and as a ‘find me’ signal that stimulates chemotaxis of immune cells towards dying cells³. When released during apoptotic cell death, CX3CL1 acts as a mediator of adaptive immune response.

Disruption of the CX3CL1/CX3CR1 pathway can lead to neurotoxic or neuroprotective responses, depending on the type of destructive factor, the CNS area, and the local concentrations of CX3CL1 and CX3CR1¹. Abnormal CX3CL1/CX3CR1 signaling promotes activation of microglia and stimulates release of inflammatory factors, thereby affecting the pathogenesis of CNS-related disorders (e.g., cerebral ischemia), mesial temporal lobe epilepsy, and neurodegenerative disease (Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis). The role of CX3CL1 in cancer is being investigated².

FSAI158R-4H6 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human CX3CL1, ALGTSPELPTGVTGSSGTR⁴. FSAI158R-4H6 detects recombinant CX3CL1 by Western blotting and presumably detects CX3CL1 protein in A549 cell lysates, where the observed multiple banding pattern is likely due to the effects of glycosylation on migration⁵. FSAI158R-4H6 does not detect CX3CL1 by immunohistochemistry, immunofluorescence, or reverse phase protein array.

CX3CL1 is expressed throughout the central nervous system, particularly in neural cells, as well as in seminal plasma, endometrial fluid, follicular fluid, small intestine, colon, testis, prostate, heart, lung, skeletal muscle, kidney, and pancreas. CX3CL1 expression can be induced in microglia, astrocytes, and vascular endothelial cells.

CX3CR1

1 Pawelec P, Ziemka-Nalecz M, Sypecka J, et al. Cells. 9(10):2277. 2020.
2 Conroy MJ, Lysaght J. Adv Exp Med Biol. 1231:1-12. 2020.
3 Naessens F, Demuynck R, Vershinina O, et al. Front Immunol. 15:1396349. 2024.
4 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
5 https://antibodies.cancer.gov/detail/CPTC-CX3CL1-1